Results 71 to 80 of about 34,967 (216)

Rivaroxaban in atrial fibrillation

, 2012
Mariano A Giorgi,1,2 Lucas San Miguel31Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, 2Department of Pharmacology, School of Medicine, Universidad Austral,
Giorgi MA, Miguel LS
core  

Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

Photonics
Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on individual physiological differences. However, current analytical methods are
Xinghao Huang, Jing Wu, Xu Wu, Yan Peng
doaj   +1 more source

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia

ClinicoEconomics and Outcomes Research, 2021
Manaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi ...
Derseh MT, Solomon K, Tamene W, Beneberu W, Yayehrad AT, Ambaye AS   +5 more
doaj  

Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Amiodarone is frequently co‐prescribed with direct oral anticoagulants (DOACs) in atrial fibrillation (AF), but its impact on early bleeding risk after DOAC initiation in older adults remains uncertain. We evaluated short‐term safety outcomes associated with concomitant amiodarone use at the time of DOAC initiation.
Isadora D. Guarino, Saman Nazarian
wiley   +1 more source

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

The DOAC‐FRAIL Study—Same Dose, Different Story: Prevalence of Deviant Direct Oral Anticoagulant Levels in Nursing Home Residents

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are prescribed using fixed dosing regimens, despite limited evidence on their pharmacokinetic behavior in nursing home residents. Participants and Setting One hundred nursing home residents are receiving apixaban, rivaroxaban, dabigatran, or edoxaban in multiple long‐term care facilities in the ...
Irme S. Franssen, Melanie J. de Jong, Lars Visseren, Daan Teerds, Dave Hellenbrand, Yvonne Henskens, Henri Spronk, Daisy J. A. Janssen, Dionne C. W. Braeken, Sander M. J. van Kuijk, Kristien Winckers, Fabienne J. H. Magdelijns   +11 more
wiley   +1 more source

Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement [PDF]

, 2017
Factor Xa inhibitors (FXaI) apixaban and rivaroxaban are used for thromboprophylaxis after major elective orthopaedic surgery. Because few patient sample studies exist, we postoperatively assessed patients undergoing unilateral total hip arthroplasty ...
Lassila, Riitta, Jarkko Leskinen, Lotta Joutsi-Korhonen, Joutsi-Korhonen, Lotta, Lauri Virtanen, Helin, Tuukka A., Riitta Lassila, Mikko Manninen, Leppilahti, Juhana, Tuukka A. Helin, Juhana Leppilahti, Virtanen, Lauri, Manninen, Mikko, Leskinen , Jarkko   +13 more
core   +1 more source

The discovery of rivaroxaban: translating preclinical assessments into clinical practice

Frontiers in Pharmacology, 2013
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza, Elisabeth ePerzborn, Scott D Berkowitz   +2 more
doaj   +1 more source

Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants: A Prospective Cohort Study on Bleeding Outcomes

Oral Diseases, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are the first‐line therapy for stroke prevention in non‐valvular atrial fibrillation and venous thromboembolism. While evidence supports their continuation during routine dental procedures such as tooth extractions, data on oral soft tissue biopsies remain limited.
Rossana Izzetti, Chiara Cinquini, Antonio Barone, Marco Nisi   +3 more
wiley   +1 more source

Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy

, 2017
Wenji Chen,1 Lina Fan,1 Yanyan Wang,2 Xiaohu Deng2 1Department of Rheumatology, Hainan Branch of Chinese People’s Liberation Army General Hospital, Sanya, 2Department of Rheumatology, Chinese People’s Liberation Army General Hospital, Beijing,
Fan L, Chen W, Deng XH, Wang Y
core